Why Wall Street Thinks Novavax Is a No-Brainer Stock to Buy Right Now
One of the following statements is false while the others are true:
If you guessed that the third statement is false, pat yourself on the back. Novavax definitely is late in entering the COVID-19 vaccine market and still hasn't won authorization for its vaccine in the U.S. Novavax's shares really have sunk like a brick since the fourth quarter of 2021.
However, analysts aren't pessimistic about the vaccine stock at all. There's a good case to be made that Wall Street thinks that Novavax is a no-brainer stock to buy right now.
Source Fool.com
